Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells

Wang,Cheng; Zhu,Zi‑Man; Liu,Cheng‑Li; He,Xiao‑Jun; Zhang,Hong‑Yi; Dong,Jia‑Hong

doi:10.3892/mmr.2015.3257

Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells

Authors:
- Cheng Wang
- Zi‑Man Zhu
- Cheng‑Li Liu
- Xiao‑Jun He
- Hong‑Yi Zhang
- Jia‑Hong Dong
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Air Force General Hospital, PLA, Beijing 100142, P.R. China, Department of Hepatobiliary Surgery, First Hospital Affiliated to PLA General Hospital, Beijing 100048, P.R. China, Department of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, P.R. China
Published online on: January 26, 2015 https://doi.org/10.3892/mmr.2015.3257
Pages: 4101-4108
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The pathogenesis of hepatocellular carcinoma (HCC) is thought to involve the interaction of numerous genes. Identification of these genes and proteins which regulate liver carcinogenesis is critical for the exploration of novel targeted therapies. Yes‑associated protein (YAP) and large tumor suppressor 1 (LATS1) are associated with HCC cells. LATS1 is an upstream inhibitory factor of YAP in the Hippo pathway. The aim of the present study was to measure the expression of LATS1 in Yap‑downregulated cancer cells. Immunohistochemistry was used to determine YAP and LATS1 levels in HCC tissue samples. High YAP‑expressing cell lines were selected from two human hepatocellular carcinoma cells with different metastatic potential. In addition, changes in cell growth rates and LATS1 expression in human HCC 97H cells, in which YAP had been knocked down using RNA interference (RNAi). The proliferation of cells was evaluated using an MTS assay and changes in the progression of cell division were assessed through cell cycle analysis. Western blot analysis was then used to determine YAP and LATS1 expression levels in 97H cells. The results of the present study demonstrated that overexpression of YAP was negatively correlated with LATS1 expression in HCC cells (P=0.016). Knockdown of YAP using lentivirus‑small hairpin (sh)RNA significantly inhibited 97H cell growth; in addition, the downregulation of YAP protein levels (33.4%) was accompanied by downregulation of LATS1 protein levels (68.5%). In conclusion, these results demonstrated that as an inhibitor of YAP, LATS1 was decreased via downregulation of YAP using RNAi. This therefore indicated that the change in YAP levels in HCC cells may regulate LATS1 in a feedback manner.

View Figures

View References

1	Simonetti RG, Camma C, Fiorello F, Politi F, D’Amico G and Pagliaro L: Hepatocellular carcinoma. a worldwide problem and the major risk factors. Dig Dis Sci. 36:962–972. 1991. View Article : Google Scholar : PubMed/NCBI
2	Carr BI: Hepatocellular carcinoma: current management and future trends. Gastroenterology. 127(5 Suppl 1): S218–S224. 2004. View Article : Google Scholar : PubMed/NCBI
3	Zhao B, Ye X, Yu J, et al: TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI
4	Zhao B, Wei X, Li W, et al: Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21:2747–2761. 2007. View Article : Google Scholar : PubMed/NCBI
5	Zender L, Spector MS, Xue W, et al: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 125:1253–1267. 2006. View Article : Google Scholar : PubMed/NCBI
6	Xu MZ, Yao TJ, Lee NP, et al: Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
7	Wang C, Zhang L, He Q, et al: Differences in yes-associated protein and mrna levels in regenerating liver and hepatocellular carcinoma. Mol Med Rep. 5:410–414. 2012.
8	Hao Y, Chun A, Cheung K, Rashidi B and Yang X: Tumor suppressor LATS1 is a negative regulator of oncogene yap. J Biol Chem. 283:5496–5509. 2008. View Article : Google Scholar
9	Li H, Wolfe A, Septer S, et al: Deregulation of hippo kinase signalling in human hepatic malignancies. Liver Int. 32:38–47. 2012. View Article : Google Scholar
10	St John MA, Tao W, Fei X, et al: Mice deficient of lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet. 21:182–186. 1999. View Article : Google Scholar : PubMed/NCBI
11	Li Y, Tang ZY, Ye SL, et al: Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol. 7:630–636. 2001.
12	Tian J, Tang ZY, Ye SL, et al: New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer. 81:814–821. 1999. View Article : Google Scholar : PubMed/NCBI
13	Ramachandran V, Arumugam T, Wang H and Logsdon CD: Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res. 68:7811–7818. 2008. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
15	Liu XS, Jiang J, Jiao XY, Wu YE, Lin JH and Cai YM: Lycorine induces apoptosis and down-regulation of Mcl-1 in human leukemia cells. Cancer Lett. 274:16–24. 2009. View Article : Google Scholar
16	Zhang J, Smolen GA and Haber DA: Negative regulation of YAP by LATS1 underscores evolutionary conservation of the drosophila hippo pathway. Cancer Res. 68:2789–2794. 2008. View Article : Google Scholar : PubMed/NCBI
17	Xu MZ, Chan SW, Liu AM, et al: AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene. 30:1229–1240. 2010. View Article : Google Scholar : PubMed/NCBI
18	Camargo FD, Gokhale S, Johnnidis JB, et al: YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 17:2054–2060. 2007. View Article : Google Scholar : PubMed/NCBI
19	Zhang X, George J, Deb S, et al: The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
20	Kim JM, Kang DW, Long LZ, et al: Differential expression of yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non-small-cell lung carcinoma. Hum Pathol. 42:315–323. 2011. View Article : Google Scholar
21	Visser S and Yang X: LATS tumor suppressor: a new governor of cellular homeostasis. Cell cycle. 9:3892–3903. 2010. View Article : Google Scholar : PubMed/NCBI
22	Chow A, Hao Y and Yang X: Molecular characterization of human homologs of yeast MOB1. Int J Cancer. 126:2079–2089. 2010.
23	Xiao L, Chen Y, Ji M and Dong J: KIBRA regulates hippo signaling activity via interactions with large tumor suppressor kinases. J Biol Chem. 286:7788–7796. 2011. View Article : Google Scholar : PubMed/NCBI
24	Ho KC, Zhou Z, She YM, Chun A, Cyr TD and Yang X: Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability [corrected]. Proc Natl Acad Sci USA. 108:4870–4875. 2011. View Article : Google Scholar
25	Yeung B, Ho KC and Yang X: WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells. PLoS One. 8:e610272013. View Article : Google Scholar : PubMed/NCBI